Our present findings also strongly suggest that IL-8 expression and the infiltration of CD163-positive M2 macrophages in the tumor microenvironment might be biomarkers for affecting and for predicting the clinical outcome of patients with any stage of OSCC, including advanced OSCC (Stage III/IV). The gene discussed is CD163; the disease is neoplasm.